Patient Care Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Patient Care Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Keio University, Japan
New findings from Keio University, Japan, described
January 14th, 2007
New findings from Keio University, Japan, described. This trend article about Keio University, Japan, is an immediate alert from NewsRx to identify developing directions of research. Study 1: Researchers detail in "Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus," new data in chemotherapy. According to recent research published in the journal Antimicrobial Agents and Chemotherapy, "Arbekacin, a derivative of dibekacin, is an aminoglycoside developed and widely used in Japan for the treatment of patients infected with methicillin-resistant Staphylococcus aureus (MRSA). The...
Source: Patient Care Law Weekly (2007-01-14)
|
